用芦可替尼和达沙替尼治疗的JAK2 V617F阳性真性红细胞增多症与BCR-ABL阳性慢性粒细胞白血病并存病例 - Suppr

Suppr

超能文献

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

作者信息

Zhou A, Knoche E M, Engle E K, Fisher D A C, Oh S T

机构信息

Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.

出版信息

Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77.

DOI:10.1038/bcj.2015.77

PMID:26430722

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4635189/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b8f/4635189/136260f39795/bcj201577f1.jpg

相似文献

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.用芦可替尼和达沙替尼治疗的JAK2 V617F阳性真性红细胞增多症与BCR-ABL阳性慢性粒细胞白血病并存病例

Blood Cancer J. 2015 Oct 2;5(10):e351. doi: 10.1038/bcj.2015.77.

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.一名同时患有真性红细胞增多症和慢性髓性白血病的患者：两种疾病的动态变化。

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.JAK2V617F阳性真性红细胞增多症和费城染色体阳性慢性髓性白血病：一例患有两种不同骨髓增殖性疾病的患者。

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21.

[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].[达沙替尼成功治疗真性红细胞增多症患者，在13年治疗期间出现BCR-ABL阳性克隆]

Rinsho Ketsueki. 2014 Jun;55(6):687-91.

Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.在接受鲁索替尼治疗的JAK2 V617F骨髓增殖性肿瘤中BCR-ABL克隆的扩增

Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13.

Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.伊马替尼治疗后慢性粒细胞白血病患者出现新的JAK2V617F克隆并随后发展为明显的真性红细胞增多症。

Eur J Haematol. 2010 Jul;85(1):86-7. doi: 10.1111/j.1600-0609.2010.01458.x. Epub 2010 Apr 16.

Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.一名妊娠女性同时存在 JAK2 V617F 突变和 BCR-ABL 易位，患有真性红细胞增多症。

Med Oncol. 2011 Dec;28(4):1555-8. doi: 10.1007/s12032-010-9570-8. Epub 2010 May 25.

A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.双重阳性骨髓增殖性肿瘤 1 例：诊断和治疗的挑战。

Indian J Pathol Microbiol. 2021 Oct-Dec;64(4):820-823. doi: 10.4103/IJPM.IJPM_977_20.

[BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation].[一名携带JAK2-V617F突变的继发性骨髓纤维化患者出现BCR-ABL1阳性慢性髓性白血病]

Rinsho Ketsueki. 2017;58(4):298-302. doi: 10.11406/rinketsu.58.298.

BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.表现为真性红细胞增多症的伴红细胞增多的BCR-ABL1阳性慢性髓性白血病：一例报告

J Med Case Rep. 2015 Apr 8;9:30. doi: 10.1186/1752-1947-9-30.

引用本文的文献

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.同时存在JAK2 V617F和BCR::ABL1的患者的临床、形态学和遗传学特征

Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6.

Treatment of V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report.用芦可替尼和氟马替尼治疗V617F阳性原发性骨髓纤维化和晚期慢性粒细胞白血病：病例报告

Ann Med Surg (Lond). 2025 Feb 28;87(3):1750-1754. doi: 10.1097/MS9.0000000000003075. eCollection 2025 Mar.

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib.酪氨酸激酶抑制剂与芦可替尼联合治疗 Jak2 阳性骨髓纤维化和 Bcr-Abl 阳性慢性粒细胞白血病并存的情况

Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025023. doi: 10.4084/MJHID.2025.023. eCollection 2025.

Co-occurrence of mutation and translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination.慢性骨髓增殖性肿瘤中突变与易位的同时出现：一种潜在的混淆性基因组合。

Front Oncol. 2024 Jan 12;13:1329298. doi: 10.3389/fonc.2023.1329298. eCollection 2023.

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.经典骨髓增殖性肿瘤的细胞形态学诊断：分子生物学时代

Cells. 2023 Mar 20;12(6):946. doi: 10.3390/cells12060946.

A 68-Year-Old Man with a Cytogenetic Diagnosis of Chronic Myeloid Leukemia and Bone Marrow Findings of Philadelphia Chromosome Translocation Between the Long Arm of Chromosomes 9 and 22, Leading to the BCR-ABL1 Fusion Gene and V617F Mutation in the JAK2 Gene.一位 68 岁男性，细胞遗传学诊断为慢性髓性白血病，骨髓发现染色体 9 号和 22 号长臂之间的费城染色体易位，导致 BCR-ABL1 融合基因和 JAK2 基因 V617F 突变。

Am J Case Rep. 2023 Mar 3;24:e938488. doi: 10.12659/AJCR.938488.

is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia.对于一名原发性血小板增多症患者，在发生JAK2V617F突变后出现慢性髓性白血病是一种继发事件。

Blood Sci. 2022 Aug 1;4(4):199-204. doi: 10.1097/BS9.0000000000000129. eCollection 2022 Oct.

Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report.慢性髓性白血病伴极重度血小板增多症患者采用伊马替尼治疗后达到长期分子缓解：罕见 e14a3(b3a3)BCR::ABL1 转录本病例报告。

Curr Oncol. 2022 Oct 28;29(11):8171-8179. doi: 10.3390/curroncol29110645.

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?对于同时患有骨髓纤维化和慢性粒细胞白血病（CML）的患者，异基因移植是一种选择吗？

Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021062. doi: 10.4084/MJHID.2021.062. eCollection 2021.

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.成功治疗一名同时存在Janus激酶2（JAK2）R795S突变和断点簇区域-ABL1（BCR-ABL1）融合的慢性粒细胞白血病患者：病例报告及文献综述

Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151.

本文引用的文献

Imatinib and ruxolitinib association: first experience in two patients.伊马替尼与芦可替尼联合应用：两例患者的首次经验

Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.

BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.在真性红细胞增多症患者发展为慢性髓性白血病的过程中，BCR-ABL1是JAK2V617F之后的继发事件。

Blood. 2013 Feb 14;121(7):1238-9. doi: 10.1182/blood-2012-11-467787.

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.慢性粒细胞白血病从骨髓增殖性疾病背景中出现：JAK2V617F作为BCR-ABL易位的潜在危险因素。

Clin Lymphoma Myeloma. 2009 Oct;9(5):E25-9. doi: 10.3816/CLM.2009.n.080.

JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.JAK2-V617F突变与费城染色体阳性慢性髓性白血病

Leuk Res. 2009 Nov;33(11):e212-3. doi: 10.1016/j.leukres.2009.06.011. Epub 2009 Jul 9.

Leukemia. 2008 Jul;22(7):1454-5. doi: 10.1038/sj.leu.2405088. Epub 2008 Feb 21.

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.伴有BCR-ABL融合及JAK2V617F突变的慢性骨髓增殖性疾病

Leukemia. 2008 May;22(5):1059-62. doi: 10.1038/sj.leu.2404993. Epub 2007 Nov 1.

Insights into JAK2-V617F mutation in CML.慢性粒细胞白血病中JAK2-V617F突变的见解。

Lancet Oncol. 2007 Oct;8(10):864-6. doi: 10.1016/S1470-2045(07)70295-4.

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.骨髓增殖性肿瘤的分类与诊断：2008年世界卫生组织标准及即时诊断算法

Leukemia. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Epub 2007 Sep 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验